GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Merus Labs International Inc (NAS:MSLI) » Definitions » Altman Z-Score

Merus Labs International (Merus Labs International) Altman Z-Score : 0.66 (As of Apr. 26, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Merus Labs International Altman Z-Score?

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Merus Labs International has a Altman Z-Score of 0.66, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for Merus Labs International's Altman Z-Score or its related term are showing as below:


Merus Labs International Altman Z-Score Historical Data

The historical data trend for Merus Labs International's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merus Labs International Altman Z-Score Chart

Merus Labs International Annual Data
Trend Sep07 Sep08 Sep09 Sep10 Sep11 Sep12 Sep13 Sep14 Sep15 Sep16
Altman Z-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.25 0.43 0.51 1.33 0.43

Merus Labs International Quarterly Data
Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.51 0.53 0.43 0.35 0.44

Competitive Comparison of Merus Labs International's Altman Z-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Merus Labs International's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Merus Labs International's Altman Z-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Merus Labs International's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where Merus Labs International's Altman Z-Score falls into.



Merus Labs International Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Merus Labs International's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*-0.0328+1.4*-0.2238+3.3*-0.0137+0.6*1.2573+1.0*0.3029
=0.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Mar. 2017:
Total Assets was $261.13 Mil.
Total Current Assets was $34.98 Mil.
Total Current Liabilities was $43.53 Mil.
Retained Earnings was $-58.43 Mil.
Pre-Tax Income was -0.601 + -4.38 + 0.273 + -3.764 = $-8.47 Mil.
Interest Expense was -1.44 + -1.292 + -0.343 + -1.811 = $-4.89 Mil.
Revenue was 16.918 + 19.543 + 22.727 + 19.898 = $79.09 Mil.
Market Cap (Today) was $152.23 Mil.
Total Liabilities was $121.08 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(34.979 - 43.532)/261.132
=-0.0328

X2=Retained Earnings/Total Assets
=-58.431/261.132
=-0.2238

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-8.472 - -4.886)/261.132
=-0.0137

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=152.230/121.077
=1.2573

X5=Revenue/Total Assets
=79.086/261.132
=0.3029

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

Merus Labs International has a Altman Z-Score of 0.66 indicating it is in Distress Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


Merus Labs International  (NAS:MSLI) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


Merus Labs International Altman Z-Score Related Terms

Thank you for viewing the detailed overview of Merus Labs International's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Merus Labs International (Merus Labs International) Business Description

Traded in Other Exchanges
N/A
Address
Merus Labs International Inc was incorporated on October 1, 2012 in British Columbia. The Company is a specialty pharmaceutical company. It acquires prescription medicines in various categories which include on patent but at maturity stage of product life cycle; branded generics; under promoted products; Niche market pharmaceuticals; and products with annual sales below critical threshold for large pharma. The Company competes with multinational pharmaceutical development corporations to small, single product companies that may limit their activities to a particular therapeutic area or region or territory.

Merus Labs International (Merus Labs International) Headlines